Brind.

Alkermes to Present Clinical Trial Results for Sleep Medicine Drugs in Maastricht

1 report, 1 independent Updated Tue 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Alkermes announced plans to present research findings at the European Sleep Research Society's 28th Congress in Maastricht. The company will share new data from the Vibrance-1 Phase 2 study of alixorexton, as well as detailed positive results from the REVITALYZSM Phase 3 study evaluating LUMRYZ. The presentations cover treatments for narcolepsy and idiopathic hypersomnia.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

The presentation of clinical trial results for alixorexton and LUMRYZ provides information on the efficacy and safety of Alkermes' sleep medicine portfolio. These findings are relevant to the commercial viability and regulatory pathway of the company's products.

From finanznachrichten.de

Who's involved

  • AlkermesCompany presenting research on its sleep medicine portfolio.
  • Giuseppe PlazziItalian neurologist and researcher involved in the research.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped